Key Highlights

● Shares closed at $3.23 at their last session, up 0.94% on the day.

● KORU Medical reported second-quarter 2026 net revenues of about $12.0 million, up about 18.2% year over year, with international core Revenue up about 59.1%.

● The company achieved Net Income of about $0.25 million, its first quarterly profit since 2019.

● KORU updated its full-year 2026 guidance to about $47.5 million to $48.5 million in revenue with positive adjusted EBITDA.

KORU Medical Systems (NASDAQ:KRMD) shares closed at $3.23 at their last session, up 0.94% on the day, as the maker of subcutaneous drug-delivery devices for at-home and ambulatory infusion delivered strong revenue growth and achieved its first profit since 2019. For investors, the combination of accelerating growth and a return to profitability is what makes the company worth watching closely.

KORU Medical develops and sells large-volume subcutaneous infusion systems, such as its Freedom60 and FreedomEDGE syringe infusion drivers, that enable patients to self-administer certain drug therapies at home or in ambulatory settings.

Latest Developments

In its second-quarter 2026 results, KORU Medical reported net revenues of about $12.0 million, up about 18.2% year over year, with domestic core revenue up about 12.4% to about $8.0 million and international core revenue up about 59.1% to about $3.5 million. The company achieved net income of about $0.25 million (about $0.01 per diluted share), its first quarterly profit since 2019, and expanded gross Margin to about 65.1% from 63.5% on lower Manufacturing costs and higher average selling prices.

It updated its full-year 2026 guidance to about $47.5 million to $48.5 million in revenue (about 15% to 18% growth) with positive adjusted EBITDA and gross margin of about 62% to 64%, pointing to durable, profitable growth.

Financial and Business Position

KORU Medical's strong revenue growth, its return to profitability and its margin expansion reflect increasing adoption of its subcutaneous drug-delivery systems both domestically and internationally, and its partnerships with drug makers for novel therapies offer additional growth potential.

Stock-Market Context

Shares closed at $3.23 at their last session, up 0.94% on the day. The stock carries a strong-buy rating, and the recent gain reflects its accelerating growth and newfound profitability. The watch-closely case rests on continued domestic and international revenue growth, sustained profitability and margin strength, and expanding novel-therapy partnerships. The cautionary case is the company's small size and competition.

A Milestone That Reframes the Investment Case

KORU Medical's quarter delivered a milestone that reframes the investment case: its first quarterly profit since 2019. The company makes subcutaneous infusion systems, the Freedom60 and FreedomEDGE drivers, that let patients self-administer certain drug therapies at home or in ambulatory infusion centers, tapping the broad healthcare shift toward convenient, lower-cost, subcutaneous delivery.

Revenue grew about 18%, with a particularly strong 59% surge internationally, and gross margin expanded past 65% on lower manufacturing costs and better pricing, driving the return to profitability. Just as important for the long term are KORU's partnerships with drug makers, which can position its devices as the delivery method for novel therapies and create durable, therapy-linked demand.

Investors watching this story will want to see the double-digit revenue growth and newfound profitability continue while novel-therapy partnerships expand. For investors, the decisive factors are whether this at-home infusion niche supports durable, profitable growth rather than a single strong stretch.